Lung Cancer Research

Uniting Against Lung Cancer believes innovative research holds the key to a cure for lung cancer. To that end, UALC is funding lung cancer research across the country. Since 2003, Uniting has awarded grants to the most promising researchers at nationally-recognized cancer research institutions. Learn more about applying for a lung cancer research grant with UALC.

Uniting Against Lung Cancer has:

Awarded 72 lung cancer research grants since the organization was founded
Funded research in 22 states at 44 different institutions in eight years of funding
Assembled the nation's leading cancer clinical and research physicians to sit on our Medical Committee to direct the research grant funding
Become a leading source of private funding in the lung cancer research field

Today Uniting Against Lung Cancer is an important part of the lung cancer research equation and allows families and other groups make a tangible contribution toward finding a cure for this disease.

Institution

Show recipients in

2010

Trever Bivona, MD, PhD

EGFR-targeted therapies are initially very successful in patients with EGFR-activating mutations, but those patients eventually become resistant. In some cases, patients develop an additional...

| More…
Lauren Averett Byers, MD, MS and John Heymach, MD

Small cell lung cancer is highly aggressive, with most patients quickly becoming resistant to standard chemotherapy. New molecularly targeted therapies are needed. Drs. Byers and Heymach are...

| More…
James DeGregori, PhD

Dr. DeGregori is seeking ways to overcome resistance to EGFR-targeted therapies. Dr. DeGregori and his team identified a number of other targets that could be inhibited to increase...

| More…
Sarah Freemantle, PhD

MicroRNAs are small RNA molecules that can control expression of almost one-third of all known genes. Dr. Freemantle and colleagues have shown increased expression of one of these microRNAs, miRNA...

| More…
Heidi Greulich, PhD

Molecularly-targeted therapies have proven more effective than standard chemotherapy in the treatment of lung cancer. In many cases, genes activated by a specific mutation have shown to be...

| More…
Christine Lovly, MD, PhD

Molecularly-targeted therapies have proven more effective than standard chemotherapy in the treatment of lung cancer. For example, patients harboring EGFR mutations initially respond very well to...

| More…
Don Nguyen, PhD

A long-standing clinical observation is that by the time cancers have spread to other organs, they are generally untreatable. In the case of lung cancer, tumors acquire resistance to different...

| More…
Paul Paik, MD

Many lung cancer patients who have mutations to the EGFR gene initially respond well to EGFR-targeted therapies; unfortunately, patients can quickly develop resistance to this therapy. However, it...

| More…
Katerina Politi, PhD

Many lung cancer patients who have mutations to the EGFR gene initially respond well to EGFR-targeted therapies; unfortunately, patients can quickly develop resistance to this therapy. In 50% of...

| More…
Julien Sage, PhD

Early detection of cancer remains one of the most important factors in successful treatment. Using a preclinicalmodel of small cell lung cancer, Dr. Sage will be investigating novel blood...

| More…

Lung Cancer Research

2010

Research

Spread the word

Find us on: